ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Ono Pharmaceutical will acquire Deciphera Pharmaceuticals, which specializes in kinase inhibitor drugs to treat cancer, for $2.4 billion. Deciphera’s drug ripretinib, marketed as Quinlock, is approved in the US and 40 other countries to treat advanced gastrointestinal stromal tumors. The company expects to submit its drug candidate vimseltinib, which is meant to treat tenosynovial giant cell tumors, to US and European regulators this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X